摘要
目的:探讨抑亢散联合甲巯咪唑治疗毒性弥漫性甲状腺肿(Graves痫)时,对甲状腺功能、甲状腺体积及突眼等的影响。方法:将126例Graves痫患者随机分为两组,每组63例,治疗组采用抑亢散联合甲巯咪唑治疗,抑亢散每次1袋,bid,甲巯咪唑每次10mg,tid,对照组仅服甲巯咪唑,剂量同前、治疗后15和30d随访,以后1~2个月随访1次,随访6个月以上,每次均测定游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、抗甲状腺过氧化物酸抗体(TPOAb)、抗甲状腺球蛋白抗体(TGAb)、甲状腺体积和患者的突眼度,了解并评价患者治疗后的疗效。结果:除对照组15d时症状和体征改变不明显外,两组治疗后症状及体征均有改善(P〈0.01);改善甲亢心悸、恶热、多汗、食欲亢进、消瘦等,两组比较差异有显著性(P〈0.01);两组TPOAb,TFGAb均逐渐下降,3和6个月时治疗组对TPOAb、TGAb、突眼及甲状腺肿大的显效率、有效率比于对照组(P〈0.05,P〈0.01)。结论:抑亢散联合甲巯咪唑治疗Graves病短期内可改善甲状腺肿症状和体征,提高甲状腺肿和甲亢性突眼的疗效,是值得推广的一种临床治疗方法:
Objective:To investigate the effect of Yikang powder combined with tapazol in the patients with (;raves disease(GD). Methods: 126 cases of GD were randomly divided into two groups. Test group was treated with Yikang powder(one pouch,bid) combined with tapazol(10mg,tid). Control group was treated with tapazol a- lone. All subjects were evaluated with serum FT3, FT4, TPOAb, TGAb levels, goitre volume and exophthalmos at 15 and 30 d after therapy,and then every 1 - 2 month for all of the foilow-up period over 6 months. Results:The clinical symptoms and signs were significantly improved after treatment in both groups,except control group in 15 days (P 〈 0.01 ). The efficacy on improving palpitation, aversion to heat, sweating, bulimia and maransis was better in the test group than that in the control group respeetively (P 〈 0.01 ). TPOAb and TGAb level was decreased gradu- ally. After 6 months,tile differences of the excellence rate and effective rate between the two groups were significant in TPOAb,TGAb, goilre volnme and exophthahnos(P 〈 0. 05, P 〈 0. 01 ). Conclusion : Yikang powder plus tapazol can improve thyroid clinical symptoms and signs,and it showed effect on adjusting goiter volume and exophthahnos.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2010年第1期39-41,55,共4页
Chinese Journal of New Drugs
关键词
GRAVES病
抑亢散
甲巯咪唑
中西医结合
Graves diseases (GD)
Yikang pounder
tapazol
integrated traditional and western medicine